Matinas BioPharma to Present at Two Investment Conferences in October 2023
September 28 2023 - 7:00AM
Matinas BioPharma (NYSE American: MTNB), a clinical-stage
biopharmaceutical company focused on redefining the intracellular
delivery of small molecules and small oligonucleotides with its
lipid nanocrystal (LNC) platform technology, announces that Jerome
D. Jabbour, Chief Executive Officer, will present a company
overview and hold meetings with institutional investors at two
upcoming investment conferences:
- Dawson James Small Cap
Growth Conference being held Thursday, October 12 at the
Wyndham Grand Harborside Hotel in Jupiter, Fla. The presentation is
scheduled for 3:30 p.m. Eastern time.
- The ThinkEquity
Conference being held Thursday, October 19 at the Mandarin
Oriental Hotel in New York City. The presentation is scheduled for
11:00 a.m. Eastern time.
A webcast of the presentation at the Dawson
James Small Cap Growth Conference will be available live on the IR
Calendar page of the Investors section of the company’s website.
The webcast will be archived for 90 days.
Institutional investors interested in arranging
a meeting with Matinas BioPharma management, please contact Jody
Cain at LHA investor relations at jcain@lhai.com.
About Matinas BioPharmaMatinas
BioPharma is a biopharmaceutical company focused on delivering
groundbreaking therapies using its lipid nanocrystal (LNC) platform
delivery technology.
Matinas’ lead LNC-based therapy is MAT2203, an
oral formulation of the broad-spectrum antifungal drug amphotericin
B, which although highly potent, can be associated with significant
toxicity. Matinas’ LNC platform provides oral delivery of
amphotericin B without the significant nephrotoxicity otherwise
associated with IV-delivered formulations. MAT2203 also allows for
safe, longer-term use outside of a hospital setting, which could
have substantial favorable pharmacoeconomic impact. MAT2203 was
successfully evaluated in the completed Phase 2 EnACT study in
cryptococcal meningitis, meeting its primary endpoint and achieving
robust survival. MAT2203 will be further evaluated as an oral
step-down monotherapy treatment following IV AMB in a single
pivotal Phase 3 study in the treatment of aspergillosis in persons
with limited treatment options who are unable to be treated with
azoles for reasons related to drug-drug interactions, resistance or
for whom these antifungal agents are unable to be used for other
clinical reasons.
In addition to MAT2203, preclinical and clinical
data have demonstrated that this novel technology can potentially
provide solutions to many of the challenges standing in the way of
achieving safe and effective intracellular delivery of both small
molecules and larger, more complex molecular cargos such as RNAi,
antisense oligonucleotides, and vaccines. The combination of its
unique mechanism of action and flexibility with routes of
administration (including oral) positions Matinas’ LNC technology
to potentially become a preferred next-generation orally available
intracellular drug delivery platform. For more information, please
visit www.matinasbiopharma.com.
Forward-looking StatementsThis
press release contains certain forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 and Private
Securities Litigation Reform Act, as amended, including those
relating to the Company's product development, clinical and
regulatory timelines, market opportunity, competitive position,
intellectual property rights, possible or assumed future results of
operations, business strategies, potential growth opportunities and
other statements that are predictive in nature. These
forward-looking statements are based on current expectations,
estimates, forecasts and projections about the industry and markets
in which we operate and management's current beliefs and
assumptions.
These statements may be identified by the use of
forward-looking expressions, including, but not limited to,
"expect," "anticipate," "intend," "plan," "believe," "estimate,"
"potential, "predict," "project," "should," "would" and similar
expressions and the negatives of those terms. These statements
relate to future events or our financial performance and involve
known and unknown risks, uncertainties, and other factors which may
cause actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements. Such
factors include those set forth in the Company's Annual Report on
Form 10-K for the year ended December 31, 2022 as well as other
documents filed by the Company from time to time thereafter with
the Securities and Exchange Commission. Prospective investors are
cautioned not to place undue reliance on such forward-looking
statements, which speak only as of the date of this press release.
The Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise.
Investor Contact
LHA Investor RelationsJody Cain
Jcain@lhai.com310-691-7100
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Jul 2024 to Aug 2024
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Aug 2023 to Aug 2024